What is the SYRE 30-day expected price range?

As of May 28, 2026, with SYRE at $72.37 and ATM IV at 72.4%, the implied 30-day one-standard-deviation range is approximately ±$15.02, or about $57.35 to $87.39. IV rank is subdued, so the priced distribution is tighter than the 1-year typical width.

What does SYRE risk-neutral density tell us?

Risk-neutral density is the probability distribution of future SYRE price implied by listed option prices. Extracted via Breeden-Litzenberger (twice-differentiating the call price function with respect to strike), it represents the pricing kernel rather than the real-world probability of outcomes. Persistent skew or fat-tail features in the density reflect how the market is pricing tail risk.

How does SYRE ATM IV translate to a probability range?

ATM IV is annualized; multiplying by sqrt(t/365) scales it to the chosen tenor. Under lognormal assumptions, the resulting standard deviation defines the ±1σ band that contains roughly 68% of outcomes, ±2σ for 95%. Empirical equity returns have fatter tails than log-normal, so the implied tail probabilities under-state realized tail frequency in stressed regimes.

Spyre Therapeutics, Inc. (SYRE) Probability Analysis

Probability analysis extracts the risk-neutral probability distribution implied by option prices. It shows the market-implied likelihood of the underlying reaching various price levels by expiration.

Spyre Therapeutics, Inc. (SYRE) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $4.47B, listed on NASDAQ, employing roughly 73 people, carrying a beta of 3.13 to the broader market. Spyre Therapeutics, Inc. Led by Cameron Turtle, public since 2016-04-07.

Snapshot as of May 28, 2026.

Spot Price: $72.37
ATM IV: 72.4%
IV Rank: 9.9%
IV Percentile: 13.1%
HV 20-Day: 56.9%
IV Skew 25Δ: 0.002

As of May 28, 2026, Spyre Therapeutics, Inc. (SYRE) at $72.37 has an ATM IV of 72.4%, implying a 30-day one-standard-deviation range of approximately ±$15.02. IV rank is 9.9% (subdued, distribution priced tighter than usual). IV percentile is 13.1%. The 25-delta skew is +0.002: roughly symmetric wings. Under lognormal assumptions roughly 68% of outcomes fall within ±1σ and 95% within ±2σ; risk-neutral probability analysis refines this by extracting the market-implied distribution directly from options prices, capturing the fat tails that real markets exhibit.

How SYRE probability analysis Data Feeds Strategy Selection

Strategy selection on Spyre Therapeutics, Inc. options does not derive from any single metric in isolation. The probability analysis view above sits inside a broader read: ATM IV currently sits at 72.4% and dealer gamma exposure is positive, so dealer hedging is mechanically mean-reverting. Combine the probability analysis data here with the volatility-skew surface, dealer-gamma exposure, max-pain level, and upcoming-events calendar to build a positioning thesis. Risk-defined structures (credit spreads, debit spreads, iron condors) are usually safer than naked positions while the regime is uncertain; the data on this page anchors the inputs but does not by itself constitute a trade thesis.

How to read the SYRE probability distribution

The probability cone above is the option-market-implied distribution of where Spyre Therapeutics, Inc. spot could end up at expiration. It's derived from the implied-volatility surface via a risk-neutral pricing transformation, not from historical realized returns. With ATM IV at 72.4% and spot at $72.37, the 1σ band is approximately ±25.0% over a 30-day horizon. Recent realized HV-20 of 56.9% runs 15.5 vol points below the current implied, suggesting the chain is pricing more dispersion than the underlying has been delivering.

SYRE risk-neutral vs real-world probabilities

The probabilities derived from option prices reflect the market's risk-adjusted view, not the realized statistical distribution. Risk-neutral probabilities include the equity risk premium and skew preferences priced into options, so they tend to overstate tail probability and understate upside drift relative to actually-realized outcomes. For probability-of-touch calculations and assignment-risk modeling, risk-neutral is the right benchmark. For position-sizing your own conviction, blend with realized-volatility-based statistics from the HV columns.

Trading the SYRE distribution

Probability-driven strategies aim to capture mispricings between the implied distribution and your own probability assessment. Premium-selling structures (credit spreads, iron condors, cash-secured puts) profit when the implied distribution overprices tail probability relative to realized; premium-buying (debit spreads, long calls/puts, long straddles) profits in the reverse. With SYRE IV rank at 9.9%, the chain is pricing tighter tails than recent realized history; buyers get cheaper optionality but need a real catalyst to monetize. Always pair probability-driven strategy selection with a stop loss or wing-defined risk - the implied distribution is a snapshot, and regime shifts can invalidate it intraday.

Learn how risk-neutral density is reported and how to read the data →

Frequently asked SYRE probability analysis questions

What is the SYRE 30-day expected price range?: As of May 28, 2026, with SYRE at $72.37 and ATM IV at 72.4%, the implied 30-day one-standard-deviation range is approximately ±$15.02, or about $57.35 to $87.39. IV rank is subdued, so the priced distribution is tighter than the 1-year typical width.
What does SYRE risk-neutral density tell us?: Risk-neutral density is the probability distribution of future SYRE price implied by listed option prices. Extracted via Breeden-Litzenberger (twice-differentiating the call price function with respect to strike), it represents the pricing kernel rather than the real-world probability of outcomes. Persistent skew or fat-tail features in the density reflect how the market is pricing tail risk.
How does SYRE ATM IV translate to a probability range?: ATM IV is annualized; multiplying by sqrt(t/365) scales it to the chosen tenor. Under lognormal assumptions, the resulting standard deviation defines the ±1σ band that contains roughly 68% of outcomes, ±2σ for 95%. Empirical equity returns have fatter tails than log-normal, so the implied tail probabilities under-state realized tail frequency in stressed regimes.